Lisinopril + HydrochlorothiazideThird Party Manufacturing in India

Lisinopril plus Hydrochlorothiazide is a fixed-dose combination that works through two complementary mechanisms to achieve blood pressure control. Lisinopril competitively inhibits angiotensin converting enzyme, preventing the conversion of angiotensin I to angiotensin II, a powerful vasoconstrictor. This reduces peripheral vascular resistance, decreases aldosterone secretion, and promotes sodium excretion while preserving potassium. Hydrochlorothiazide acts on the distal convoluted tubule of the nephron, inhibiting the sodium-chloride symporter to block reabsorption of sodium and chloride ions, which increases water excretion and reduces plasma volume. The combination is particularly effective because the diuretic effect of hydrochlorothiazide activates the renin-angiotensin system, which is then blocked by lisinopril, creating a synergistic antihypertensive effect. This dual mechanism allows for better blood pressure control at lower doses of each component, reducing dose-related side effects while improving treatment adherence through once-daily dosing.

Therapeutic Uses

Lisinopril + Hydrochlorothiazide is prescribed for the treatment of:

• Hypertension: Second-line therapy for patients whose blood pressure is not adequately controlled with lisinopril or hydrochlorothiazide monotherapy.
• Combination Therapy: Synergistic blood pressure reduction leveraging complementary mechanisms of action for improved outcomes.
• Edema with Hypertension: Manages fluid retention in hypertensive patients with concurrent edema from heart failure or other causes.

Why Manufacturers Choose Lisinopril + Hydrochlorothiazide

This fixed-dose combination is one of the most widely prescribed antihypertensive products globally, reflecting the established efficacy and safety of both component molecules. The combination is particularly popular in the Indian market where multidrug therapy is common for achieving blood pressure targets. Manufacturers benefit from the cost synergies of producing both active ingredients and the multiple strength permutations 10mg+12.5mg and 20mg+12.5mg that allow product line differentiation for PCD franchise partners. The combination enjoys strong formulary inclusion and physician familiarity, ensuring consistent demand across institutional and retail channels.